{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:41:09Z","timestamp":1761986469119},"reference-count":10,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Our objective was to evaluate the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A (IL-17A) monoclonal antibody (MAb) secukinumab. We used an open-label, parallel-group, randomized single-center study of 50 healthy subjects. Subjects received a single 150-mg dose of secukinumab or no treatment, followed by vaccination with inactivated trivalent subunit influenza virus and conjugate group C meningococcal vaccine (Agrippal and Menjugate, respectively) 2 weeks later. Primary efficacy variables were responses of \u22654-fold increases in antibody titer (hemagglutination inhibition [HI; for influenza virus] and serum bactericidal assay [SBA; for\n            <jats:named-content content-type=\"genus-species\">Neisseria meningitides<\/jats:named-content>\n            ]) for meningococcus and influenza (at least two out of three serotypes), both at 4 weeks postvaccination. All subjects randomized to secukinumab (\n            <jats:italic>n<\/jats:italic>\n            = 25) or the control (\n            <jats:italic>n<\/jats:italic>\n            = 25) completed the study. Antibody responses to vaccinations measured at 4 weeks were comparable in both groups, with \u22654-fold increased responses following influenza virus vaccination of 20\/25 (80%) for both groups and following meningococcal vaccination of 19\/25 (76%) for the secukinumab group and 18\/25 (72%) for the control group. Differences between groups were 0% (90% confidence intervals [CI], 19 and 19%) and 4% (90% CI, 16 and 24%) for influenza virus and meningococcal vaccines, respectively. Antibody responses were comparable between the 2 groups at different time points. Headache was the most frequently reported adverse effect. No deaths or serious adverse events were reported. Blockade of IL-17A by secukinumab does not appear to interfere with efficacy of influenza and meningococcal vaccinations, as assessed by the achievement of protective antibody levels. A protective (\u22654-fold) immune response to both vaccinations at 4 weeks was achieved in 80 and 76% of subjects exposed to secukinumab and the control, respectively.\n          <\/jats:p>","DOI":"10.1128\/cvi.00386-12","type":"journal-article","created":{"date-parts":[[2012,8,9]],"date-time":"2012-08-09T06:04:48Z","timestamp":1344492288000},"page":"1597-1602","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":59,"title":["Treatment with the Interleukin-17A-Blocking Antibody Secukinumab Does Not Interfere with the Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects: Results of an Open-Label, Parallel-Group, Randomized Single-Center Study"],"prefix":"10.1128","volume":"19","author":[{"given":"A.","family":"Chioato","sequence":"first","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Noseda","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Stevens","sequence":"additional","affiliation":[{"name":"EMStat Ltd., Leicester, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gaitatzis","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kleinschmidt","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Picaud","sequence":"additional","affiliation":[{"name":"MEDISCIS, Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00175-10"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077552"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.12.584"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001107"},{"key":"e_1_3_2_6_2","first-page":"272","article-title":"Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab","volume":"34","author":"Kaine JL","year":"2007","unstructured":"KaineJL KivitzAJ BirbaraC LuoAY. 2007. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J. Rheumatol. 34:272\u2013279.","journal-title":"J. Rheumatol."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.08.025"},{"key":"e_1_3_2_8_2","volume-title":"The changing epidemiology of meningococcal disease among U.S. children, adolescents and young adults","author":"National Foundation for Infectious Diseases","year":"2004","unstructured":"National Foundation for Infectious Diseases. 2004. The changing epidemiology of meningococcal disease among U.S. children, adolescents and young adults. National Foundation for Infectious Diseases, Bethesda, MD."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077461"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2010.27"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2174"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00386-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00386-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:46:34Z","timestamp":1627591594000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00386-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1128\/CVI.00386-12"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00386-12","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"2012-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-07-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-09-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}